[Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].
58 women with metastatic breast cancer, non-responsive to hormone therapy, were treated with a modified CMF regimen. After progression the combination of adriamycin and vincristine was used. With CMF the response rate was 41% (10% complete remissions, 31% partial remissions), 38% showed no change, whilst progression of the disease was observed in only 21% of patients. The median duration of remission was about 8 months. Progression of the disease was treated by a combination of adriamycin and vincristine and remissions were obtained in 24% of cases. The median survival time of our patients from the time of tumour metastasis was 18.6 months and was dependent on the results of treatment.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011379:Prognosis; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Erfolge der zytostatischen Therapie beim metastasierenden Mammakarzinom.